Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOST | Q9BQB4 | 1/20 | 1.00 |
| ▸ | FPGS | Q05932 | 2/20 | 0.89 |
| ▸ | GART | P22102 | 5/20 | 0.75 |
| ▸ | DHFR | P00374 | 1/20 | 0.67 |
| ▸ | ATIC | P31939 | 3/20 | 0.65 |
| ▸ | MTHFD1 | P11586 | 2/20 | 0.63 |
| ▸ | MTHFD2 | P13995 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrahydrofolate SCHEMBL258530 | 1.00 | SOST (1.00) | SOSTFPGSGARTDHFRATIC | |
| Tetrahydrofolate SCHEMBL30051444 | 1.00 | SOST (1.00) | SOSTFPGSGARTDHFRATIC | |
| Tetrahydrofolate SCHEMBL1069545 | 1.00 | SOST (1.00) | SOSTFPGSGARTDHFRATIC | |
| Tetrahydrofolate SCHEMBL4535491 | 1.00 | SOST (1.00) | SOSTFPGSGARTDHFRATIC | |
| Tetrahydrofolate SCHEMBL9879710 | 1.00 | SOST (1.00) | SOSTFPGSGARTDHFRATIC | |
| Tetrahydrofolate SCHEMBL8030 | 1.00 | SOST (1.00) | SOSTFPGSGARTDHFRATIC | |
| Tetrahydrofolate SCHEMBL29435894 | 1.00 | SOST (1.00) | SOSTFPGSGARTDHFRATIC | |
| Tetrahydrofolate SCHEMBL2691812 | 1.00 | SOST (1.00) | SOSTFPGSGARTDHFRATIC | |
| Tetrahydrofolate SCHEMBL29870853 | 1.00 | SOST (1.00) | SOSTFPGSGARTDHFRATIC | |
| Tetrahydrofolate SCHEMBL10358931 | 0.99 | SOST (0.98) | SOSTFPGSGARTDHFRATIC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210346381-A1 | ALPHA POLYGLUTAMATED TETRAHYDROFOLATES AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2021-11-11 | — | — | US | disclosed |
| EP-3749319-A1 | ALPHA POLYGLUTAMATED TETRAHYDROFOLATES AND USES THEREOF | L.E.A.F Holdings Group LLC (US) | 2020-12-16 | — | — | EP | disclosed |
| CN-111971047-A | Gamma polyglutamated tetrahydrofolic acid and application thereof | L.E.A.F.控股集团公司 | 2020-11-20 | — | — | CN | disclosed |
| CN-110403945-A | Composite vitamin composition for promoting gastrointestinal system power and preparation method thereof | ZENSUN SHANGHAI SCIENCE & TECH LIMITED | 2019-11-05 | — | — | CN | disclosed |
| CN-108164531-B | A kind of preparation method of L-5- methyl tetrahydrofolate calcium | 江苏红豆杉药业有限公司 | 2019-11-05 | — | — | CN | disclosed |
| WO-2019157120-A1 | ALPHA POLYGLUTAMATED TETRAHYDROFOLATES AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC (US) | 2019-08-15 | — | — | WO | disclosed |
| CN-110022882-A | Promote the compound vitamin composition of gastronintestinal system power | 上海泽生科技开发股份有限公司 | 2019-07-16 | — | — | CN | disclosed |
| CN-106970230-B | A kind of homocysteine detection reagent box | 广州市伊川生物科技有限公司 | 2019-06-11 | — | — | CN | disclosed |
| CN-109182563-A | Detect the method and used kit of 20 kinds of dfrA class trimethoprim class Drug-resistant genes | 浙江大学 | 2019-01-11 | — | — | CN | disclosed |
| CN-108642169-A | Detect ten kinds of trimethoprim class Drug-resistant genetic methods and used kit | 浙江大学 | 2018-10-12 | — | — | CN | disclosed |
| US-20110092453-A1 | TREATMENTS AND PREVENTION OF HYDROCEPHALUS | THE UNIVERSITY OF MANCHESTER (GB) | 2011-04-21 | — | — | US | disclosed |
| CN-101933972-A | Nitric oxide reinforcing agent and application thereof | TING WANG | 2011-01-05 | — | — | CN | disclosed |
| CN-101663066-A | Near-infrared electromagnetic modification of cellular steady- state membrane potentials | NOMIR MEDICAL TECHNOLOGIES INC | 2010-03-03 | — | — | CN | disclosed |
| WO-2009117675-A1 | LOW ASPECT RATIO DIFFUSING FIBER TIP | NOMIR MEDICAL TECHNOLOGIES, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009117672-A2 | MODIFICATION OF CELLULAR STEADY-STATE MEMBRANE POTENTIALS IN DRUG RESISTANT BACTERIA | NOMIR MEDICAL TECHNOLOGIES,INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| EP-2089107-A2 | NEAR-INFRARED ELECTROMAGNETIC MODIFICATION OF CELLULAR STEADY- STATE MEMBRANE POTENTIALS | Nomir Medical Technologies, Inc (US) | 2009-08-19 | — | — | EP | disclosed |
| CN-101363800-A | Kit for evaluating toxic and side effect of tumor chemotherapy | SHANGHAI ZHUJIAN BIOENGINEERIN (CN) | 2009-02-11 | — | — | CN | disclosed |
| EP-2013619-A2 | REAGENTS AND METHODS FOR USING HUMAN EMBRYONIC STEM CELLS TO EVALUATE TOXICITY OF PHARMACEUTICAL COMPOUNDS&OTHER CHEMICALS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008073979-A2 | NEAR-INFRARED ELECTROMAGNETIC MODIFICATION OF CELLULAR STEADY- STATE MEMBRANE POTENTIALS | NOMIR MEDICAL TECHNOLOGIES, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2007120699-A2 | REAGENTS AND METHODS FOR USING HUMAN EMBRYONIC STEM CELLS TO EVALUATE TOXICITY OF PHARMACEUTICAL COMPOUNDS & OTHER CHEMICALS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092453-A1 | TREATMENTS AND PREVENTION OF HYDROCEPHALUS | DHFR, MTHFD1, MTHFD2 | SOST 2003/4885FPGS 13/4885GART 538/4885 |
| US-20210346381-A1 | ALPHA POLYGLUTAMATED TETRAHYDROFOLATES AND USES THEREOF | DHFR, FPGS, MTHFD1 | SOST 3884/4885FPGS 2/4885GART 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.